ALX Oncology Holdings Inc
NASDAQ:ALXO
ALX Oncology Holdings Inc
NASDAQ:ALXO
Price:
1.68
USD
-3.45%
Market Cap:
$91.1m
Relative Value
The Relative Value of one
ALXO
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 1.68 USD,
ALX Oncology Holdings Inc
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ALXO Relative Value
HIDDEN
Multiples Across Competitors
ALXO Competitors Multiples
ALX Oncology Holdings Inc Competitors
ALX Oncology Holdings Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
ALX Oncology Holdings Inc
NASDAQ:ALXO
|
90m USD | 0 | -0.9 | -0.3 | -0.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
397.7B USD | 6.7 | 170.1 | 16.5 | 23.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
182.7B USD | 5.1 | 26.2 | 18.8 | 18.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
179.8B USD | 6.2 | 22.2 | 15 | 15 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.6B USD | 10.1 | 32.1 | 23.6 | 24.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.5B USD | 5.6 | 17.7 | 14.9 | 17 | |
| AU |
|
CSL Ltd
ASX:CSL
|
86.7B AUD | 3.9 | 20.1 | 13.4 | 16.8 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.5B EUR | 14.5 | 34.2 | 58.4 | 60.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
